Save up -80% on Cariprazine

Note: this is a drug discount program, not an insurance plan.
RX BIN: 015558RX PCN: HTGroup ID: DDN6600Card Holder ID: DDN6600
Pharmacists and Patients support.

2019 Price of Vraylar

$1,20430 capsules/3 mg
price without discount in nearest pharmacy. Price may vary.

Claim your free Cariprazine discount card

We offer free Vraylar coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Cariprazine every time. What are you waiting for? Claim your prescription drug card now!

Walgreens pharmacy
Walgreens pharmacy
CVS pharmacy
CVS pharmacy
Walmart pharmacy
Walmart pharmacy
Ride AID pharmacy
Ride AID pharmacy
CVS Target pharmacy
CVS Target pharmacy
Kroger pharmacy
Kroger pharmacy
rx

Get your Prescription

safe

It’s safe and free

pharmacy

Buy drugs in pharmacy

save money

Save money each time

Cariprazine volume of distribution

Cariprazine has also large volume of distribution of up to 7.8 L/kg in the rat and 19 L/kg in the dog and distributes well to most tissues

RX Prescription
Ask Your therapeut before taking any drugs.

About RX24Drugs

2018 Statistics

discount card

Discount Cards 16,000+

benefit

Clients Benefit 29%

savings

Total savings $4,735,080

What is Cariprazine

Cariprazine is an antipsychotic drug developed by Gedeon Richter and marketed by Actavis under the trade name Vraylar. Cariprazine acts as a D2 and D3 receptor partial agonist, with high selectivity towards the D3 receptor. This mechanism is relatively unique, since many other antipsychotics are D2 and 5-HT2A agonists. Cariprazine was approved by the FDA in September 2015 and is indicated in the treatment of schizophrenia and bipolar disorder. Action on the dopaminergic systems makes it also potentially useful as an add-on therapy in major depressive disorder.

Cariprazine mechanism of action

The mechanism of action of cariprazine in schizophrenia and bipolar I disorder is unknown. However, the efficacy of cariprazine could be mediated through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Cariprazine forms two major metabolites, desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR), that have in vitro receptor binding profiles similar to the parent drug.

Dosage forms of Cariprazine

FormRouteStrength
Capsule, gelatin coatedoral1.5 mg/1
Capsule, gelatin coatedoral3 mg/1
Capsule, gelatin coatedoral4.5 mg/1

Prescription Generics

false

International Brands

Vraylar

Synonyms

trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N N dimethylurea hydrochloride

Manufacturers

Actavis Pharma, Inc.

CAS number

839712-12-8

UNII

F6RJL8B278

State

solid

Affected organisms

Humans and other mammals

Indication of Cariprazine

Cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder.

Toxicity of Cariprazine

Accidental acute overdosage (48 mg/day) was reported in one patient. This patient experienced orthostasis and sedation. The patient fully recovered the same day. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Cariprazine is not approved for the treatment of patients with dementia-related psychosis.

RX24 Drugs Disclaimer: consult your healthcare provider before buying a Cariprazine on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.

Get lower price on Cariprazine now!

What is Vraylar?

Vraylar is an antipsychotic that affects chemicals in the brain. Vraylar is used to treat schizophrenia. Vraylar is also used to treat manic or mixed episodes in people with bipolar I disorder. Vraylar is not approved for use in psychotic conditions associated with dementia. Vraylar may increase the risk of death in elderly people with dementia-related conditions.